Emcure Pharmaceuticals Reduces Poviztra® Starting Dose Price by 55% to Expand Patient Access
Pune, April 2, 2026: Emcure Pharmaceuticals Ltd. (BSE: 544210, NSE: EMCURE) announced a price revision for its weight management drug Poviztra® (semaglutide injection) across India, effective April 3, 2026. The reduced price starts at Rs. 3,999 per month for a 4-weekly dose regimen.Poviztra® is a second brand of Novo Nordisk's semaglutide injection for obesity, and Emcure is the exclusive distributor and commercializer in India. The company aims to expand access to the therapy with the revised pricing.
The following table details the price changes:
| Dosage | Old Monthly Price (MRP incl. Taxes) | Revised Monthly Price (MRP incl. Taxes) |
|---|---|---|
| Poviztra® 0.25 mg | 8,790/- | 3,999/- |
| Poviztra® 0.5 mg | 11,200/- | 4,999/- |
| Poviztra® 1 mg | 11,200/- | 5,999/- |
| Poviztra® 1.7 mg | 13,000/- | 7,999/- |
| Poviztra® 2.4 mg | 15,000/- | 8,999/- |
According to Satish Mehta, Chief Executive Officer and Managing Director, Emcure Pharma, the revised pricing is a step towards making scientifically validated weight-management therapies more accessible and affordable. He noted that India faces a growing obesity epidemic, with approximately 254 million people living with generalised obesity and 351 million with abdominal obesity.
The innovator semaglutide molecule has been on the market for nearly a decade and has been utilized in over 49 million patient years, backed by approximately 50 clinical trials.
Obesity is linked to over 230 health complications, including cardiovascular disease, type 2 diabetes, and Alzheimer's disease. Emcure Pharma stated that this price reduction reinforces its commitment to improving patient access and health outcomes.
Emcure Pharmaceuticals Ltd. is a Pune-based pharmaceutical company established in 1981. The company is ranked as the 13th largest pharma company in India in terms of Domestic Sales for the 12-month period ending October 2025. Emcure is present in over 70 countries globally.
Source:
Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.